Skip to main content

Table 2 Correlation between c-Myc and the clinicopathological characteristics in HCC tissues and adjacent tissues

From: Low expression of c-Myc protein predicts poor outcomes in patients with hepatocellular carcinoma after resection

Variables Cases c-Myc expression in HCC tissues P value c-Myc expression in adjacent tissues P value
   Low High   Low High  
Age(yrs)
  > =60 16 4(25.0%) 12(75.0%) 0.161 3(18.8%) 13(81.2%) 0.140
  < 60 68 30(44.1%) 38(55.9%) 26(38.2%) 42(61.8%)  
Sex
 Male 68 29(42.6%) 39(57.4%) 0.403 21(30.9%) 47(69.1%) 0.148
 Female 16 5(31.3%) 11(68.7%) 8(50.0%) 8(50.0%)  
HbsAg
 Positive 72 30(41.7%) 42(58.3%) 0.586 25(34.7%) 47(65.3%) 0.925
 Negative 12 4(33.3%) 8(66.7%) 4(33.3%) 8(66.7%)  
ALT(U/L)
  ≥ 80 9 3(33.3%) 6(66.7%) 0.644 5(55.6%) 4(44.4%) 0.160
 <80 75 31(41.3%) 44(58.7%)   24(32.0%) 51(68.0%)  
PLT(×109)
  > 100 74 33(44.6%) 41(55.4%) 0.036 24(32.4%) 50(67.6%) 0.273
  ≤ 100 10 1(10.0%) 9(90.0%) 5(50.0%) 5(50.0%)  
Cirrhosis
 Yes 64 22(34.4%) 42(65.6%) 0.042 19(29.7%) 45(70.3%) 0.095
 No 20 12(60.0%) 8(40.0%) 10(50.0%) 10(50.0%)  
AFP(ug/L)
  ≥ 20 48 22(45.8%) 26(51.2%) 0.248 19(39.6%) 29(60.4%) 0.260
 <20 36 12(33.3%) 24(66.7%) 10(27.8%) 26(72.2%)  
Tumor size (cm)
  ≥ 5 50 25(50.0%) 25(50.0%) 0.031 19(38.0%) 31(62.0%) 0.416
 <5 34 9(26.5%) 25(73.5%) 10(29.4%) 24(70.6%)  
Tumor number
 Single 62 21(33.9%) 41(66.1%) 0.038 20(32.3%) 42(67.7%) 0.463
 Multiple 22 13(59.1%) 9(40.9%) 9(40.9%) 13(59.1%)  
Differentiation
 I-II 62 24(38.7%) 38(61.3%) 0.580 25(40.3%) 37(59.7%) 0.061
 III 22 10(45.5%) 12(54.5%) 4(18.2%) 18(81.8%)  
TNM stage
 I 55 20(36.4%) 35(63.6%) 0.290 18(32.7%) 37(67.3%) 0.633
 II-III 29 14(48.3%) 15(51.7%) 11(37.9%) 18(62.1%)  
PVTT
 Yes 11 8(72.7%) 3(27.3%) 0.019 4(36.4%) 7(63.6%) 0.890
 No 73 26(35.6%) 47(64.4%) 25(34.2%) 48(65.8%)  
Tumor Encapsulation
Complete 64 23(35.9%) 41(64.1%) 0.130 17(26.6%) 47(73.4%) 0.006
 None 20 11(55.0%) 9(45.0%) 12(60.0%) 8(40.0%)  
Recurrence
 Yes 58 30(51.7%) 28(48.3%) 0.002 21(36.2%) 37(63.8%) 0.628
 No 26 4(15.4%) 22(84.6%) 8(30.8%) 18(69.2%)  
Complication
 No 73 27(37.0%) 46(63.0%) 0.177 27(37.0%) 46(63.0%) 0.221
 Yes 11 7(63.6%) 4(36.4%) 2(18.2%) 9(81.8%)  
  1. AFP Alpha-fetoprotein, ALT alanine aminotransferase, HBsAg hepatitis B surface antigen, PLT platelet, PVTT portal vein tumor thrombi